Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

• Published in: European journal of cancer (1990) Vol. 174; pp. 287 - 298
• Main Authors: Foy, Jean-Philippe, Karabajakian, Andy, Ortiz-Cuaran, Sandra, Boussageon, Maxime, Michon, Lucas, Bouaoud, Jebrane, Fekiri, Dorssafe, Robert, Marie, Baffert, Kim-Arthur, Hervé, Geneviève, Quilhot, Pauline, Attignon, Valéry, Girod, Angélique, Chaine, André, Benassarou, Mourad, Zrounba, Philippe, Caux, Christophe, Ghiringhelli, François, Lantuejoul, Sylvie, Crozes, Carole, Brochériou, Isabelle, Pérol, Maurice, Fayette, Jérôme, Bertolus, Chloé, Saintigny, Pierre
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Science Ltd 01.10.2022; Elsevier
• Subjects: Biopsy; Diagnostic systems; Gene expression; Head & neck cancer; Head and neck carcinoma; Immunotherapy; Inhibitors; Life Sciences; Lung cancer; Multivariate analysis; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Phenotypes; Small cell lung carcinoma; Squamous cell carcinoma; Survival; Tumors; γ-Interferon
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2022.06.034

Introduction: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours. Methods: Using gene expression profiles of 421 HNSCC, we developed a score to identify immunologically active tumours. Validation of the 'HOT' score was done in 40 HNSCC and 992 NSCLC. Stability of the 'HOT' score was tested in paired HNSCC samples from diagnostic biopsies versus surgically resected specimens, untreated versus recurrent samples, and pre-versus post-cetuximab samples in a total of 76 patients. The association between the 'HOT' score with overall survival (OS) and progression-free survival (PFS) was tested in 184 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors. Results: A 27-gene expression based 'HOT' score was correlated with: (i) PD-L1 and IDO1 expression, (ii) TCD8 infiltrate and (iii) activation of the IFN-γ pathway. The HOT score concordance when comparing diagnostic biopsies and surgically resected specimens was higher than in untreated samples versus recurrent or pre-versus post-cetuximab samples. In 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors, the HOT score was associated with an improved OS and PFS in multivariate analysis. Conclusion: The 'HOT' score is a simple and robust approach to identify real-world patients with HNSCC and NSCLC immunologically active tumours who may benefit from PD-1/PD-L1 inhibitors.